By Tiffany Hu ( September 12, 2019, 7:43 PM EDT) -- The Patent Trial and Appeal Board has agreed to review two patents covering Amgen Inc.'s blockbuster chemotherapy drug Neupogen, rejecting Amgen's argument that its validity contentions in a parallel district court case were unfairly used as a roadmap for the petitions for inter partes review....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.